PharmEasy (API Holdings Ltd) Unlisted Shares Price Today

About the Company
PharmEasy, launched in 2015 by Dharmil Sheth and Dr. Dhaval Shah, is India’s leading digital healthcare platform. The company offers a comprehensive range of services, including online medicine delivery, diagnostic tests, teleconsultations, and healthcare products. With a presence across over 18,500 pin codes, PharmEasy has established itself as a significant player in the Indian healthcare sector. In 2020, PharmEasy merged with Ascent Health and five other companies to form API Holdings, creating India’s largest online healthcare company. In 2021, it acquired a 66% stake in Thyrocare Technologies, marking the first instance of a unicorn acquiring a listed company in India.

Business Segments and Financial Performance
PharmEasy operates through multiple verticals:

• E-Pharmacy: Online ordering and delivery of medicines.

• Diagnostics: Home sample collection and testing services.

• Teleconsultation: Online doctor consultations.

• Healthcare Products: Sale of wellness and healthcare products.

In FY23, PharmEasy reported an operating revenue of ₹6,644 crore, a 16% increase from the previous year. However, the company also reported a net loss of ₹5,212 crore, primarily due to an impairment loss of ₹2,922 crore. Excluding this, the net loss stood at ₹2,290 crore, indicating a 16% reduction from the previous year. The company managed to reduce marketing expenses by over 50% and employee benefit expenses by 12%, reflecting efforts to optimize costs.

Unlisted Share Insights
As of May 2025, PharmEasy’s unlisted shares are trading at ₹8.50 per share, a significant decline from their peak of ₹140 in anticipation of the IPO. The drop is attributed to high supply in the unlisted market and the company’s financial performance